EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States…
$0.30-3.80%
报价 2026-11-17
市值
$24.8M
EV
$-54.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -98.4%
$0.30$18.85
筛选结果
pipeline · 2026-11-17Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EYPTEyePoint Pharmaceuticals, Inc. | $24.8M | -3.8% | -95.0% | 41.8% | – | – | – | |
| KODKodiak Sciences Inc. | $6.33B | -3.9% | +1783.3% | 0% | – | – | – | |
| TNGXTango Therapeutics, Inc. | $3.75B | -8.5% | -90.3% | 98.3% | – | – | – | |
| SEPNSepterna, Inc. | $1.9B | -4.0% | +149.0% | 99.4% | – | – | 16.4x | |
| NRIXNurix Therapeutics, Inc. | $1.56B | -3.3% | +749.2% | -139.4% | – | – | 4.2x | |
| SVRASavara Inc. | $988.4M | +0.3% | +21.4% | 0% | – | – | – | |
| PRMEPrime Medicine, Inc. | $698.6M | -8.4% | +110.0% | -1,025.6% | – | – | – | |
| KURAKura Oncology, Inc. | $688.2M | +5.6% | +9.0% | 94.7% | – | – | – | |
| BCAXBicara Therapeutics Inc. Common Stock | $637.3M | -1.5% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +110.0% | 0% | – | – | 10.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。